fludarabine has been researched along with Pneumonia in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (16.67) | 18.2507 |
2000's | 4 (33.33) | 29.6817 |
2010's | 6 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Beckers, MM; Daenen, S; Doorduijn, JK; Doreen Te Raa, G; Eldering, E; Kater, AP; Lankheet, NA; Liu, RD; Luijks, DM; Slinger, E; Spiering, M; Tonino, SH; van Oers, MH | 1 |
Huang, XJ; Ji, Y; Liu, DH; Liu, KY; Sun, YQ; Wang, FR; Wang, JZ; Wang, Y; Xu, LP; Yan, CH; Zhang, XH; Zhang, YY | 1 |
Annechini, G; Capria, S; D'Elia, GM; De Angelis, F; Foà, R; Pulsoni, A; Russo, E; Stefanizzi, C; Tosti, ME | 1 |
Artz, A; Bredeson, C; Burkart, J; DiPersio, J; Fernandez, HF; Kamishohara, M; Le-Rademacher, J; Mehta, J; Mineishi, S; Nakamura, Y; Pasquini, MC; Ratanatharathorn, V; Sobecks, R; Zhu, X | 1 |
Branagan, AR; Emmanouilides, C; Frankel, SR; Gregory, SA; Ioakimidis, L; Kimby, E; Lister, A; Matous, J; Morel, P; Patterson, CJ; Soumerai, JD; Treon, SP; Turnbull, B; Wasi, P | 1 |
Chiang, R; Earp, J; Gootenberg, JE; Keegan, P; Lemery, SJ; McDougal, A; Pazdur, R; Pilaro, A; Rothmann, MD; Yang, J; Zhang, J; Zhao, H | 1 |
Chao, NJ; Chino, JP; Craciunescu, O; Folz, RJ; Horwitz, ME; Kelsey, CR; Marks, LB; Rizzieri, DA; Steffey, B | 1 |
Abe, Y; Choi, I; Inaba, S; Matsushima, T; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Ohtsuka, R; Tachikawa, Y | 1 |
Bamberg, M; Belka, C; Bethge, W; Faul, C; Handgretinger, R; Heinzelmann, F; Lang, PJ; Ottinger, H | 1 |
Andreeff, M; Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Plunkett, W; Robertson, LE | 1 |
O'Brien, RK; Sparling, TG | 1 |
Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Geissler, G; Helwig, A; Jenke, A; Lutterbeck, K; Oelschlagel, U; Platzbecker, U; Plettig, R; Röllig, C; Thiede, C | 1 |
4 trial(s) available for fludarabine and Pneumonia
Article | Year |
---|---|
Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Administration Schedule; Fatigue; Female; Gene Expression Regulation, Leukemic; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Middle Aged; Nausea; NF-kappa B; Pneumonia; Pyrimidines; Thiazoles; Thrombocytopenia; Treatment Outcome; Vidarabine | 2014 |
Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Child; Cyclophosphamide; Drug Substitution; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Pneumonia; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Neutropenia; Pneumonia; Prospective Studies; Rituximab; Survival Rate; Thrombocytopenia; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Natural; Male; Middle Aged; Neoplasms; Pneumonia; Survival Analysis; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2001 |
8 other study(ies) available for fludarabine and Pneumonia
Article | Year |
---|---|
Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease Susceptibility; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; IgG Deficiency; Immunocompromised Host; Immunotherapy; Incidence; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pneumonia; Prednisone; Proportional Hazards Models; Retrospective Studies; Rituximab; Transplantation, Autologous; Vidarabine; Vincristine; Young Adult | 2015 |
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Male; Middle Aged; Myeloablative Agonists; Pneumonia; Prospective Studies; Seizures; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD20; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Fever; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neutropenia; Pneumonia; Treatment Outcome; United States; United States Food and Drug Administration; Vidarabine | 2010 |
Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.
Topics: Acute Disease; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Lung; Male; Melphalan; Middle Aged; Pneumonia; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Successful treatment with nonmyeloablative allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia complicated with pulmonary infection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Combined Modality Therapy; Cyclosporine; Cytarabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pneumonia; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Child, Preschool; Disease-Free Survival; Graft Rejection; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphatic Irradiation; Middle Aged; Muromonab-CD3; Peripheral Blood Stem Cell Transplantation; Pneumonia; Retreatment; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Bacteremia; Drug Administration Schedule; Female; Fever of Unknown Origin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pneumonia; Remission Induction; Survival Rate; Vidarabine | 1995 |
Gentamicin and fludarabine ototoxicity.
Topics: Aged; Antineoplastic Agents; Deafness; Dose-Response Relationship, Drug; Gentamicins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Pneumonia; Vidarabine | 1995 |